For Immediate Release
Chicago, IL – September 14, 2023 – Today, Zacks Investment Ideas feature highlights Novo Nordisk (
NVO Quick Quote NVO - Free Report) , Eli Lilly ( LLY Quick Quote LLY - Free Report) and AbbVie ( ABBV Quick Quote ABBV - Free Report) . "Blockbuster Status": 3 Biotechs to Buy and Hold Profitability in the Biotech Industry is Hard to Come By
The biotech sector is notorious for its sky-high research and development (R&D) costs, regulatory hurdles, and lengthy timelines to bring a drug or therapy to market. Many drugs fail clinical trials while biotech companies set others aside to focus on more encouraging opportunities. According to one study, for every 100 drugs that enter phase 1 trials, only 12 ultimately achieve phase lll (the final trial) approval. While the profitability of public biotech companies can vary significantly, most are unprofitable.
Unpredictability is a Challenge for Investors
For unsophisticated investors, investing in biotech stocks with little knowledge can be a quick way to lose money because:
Binary Events: Bios often move 50% or more after an FDA decision. If an investor finds themselves on the wrong side of a decision, a massive gap down can devastate a portfolio.
Volatility: Even when no FDA decision looms, biotech stocks can be volatile, illiquid and challenging to trade.
Lack of Profitability: Ultimately, stocks mirror their long-term fundamentals. Because most biotech stocks are unprofitable, they often underperform. The Solution: Seek Biotech Firms Achieving “Blockbuster Status”
While many challenges exist for investors looking to profit off biotech stocks, they can be overcome. However, to do so, investors must identify biotech stocks that are profitable, liquid, and have achieved
Blockbuster status refers to the successful development and commercialization of a pharmaceutical product that generates annual sales exceeding $1 billion. “blockbuster status.” New blockbuster drugs offer investors something difficult to find in most biotech stocks: a long run way of profitability. Below are 3 examples: Novo Nordisk’s Ozempic is a medication used to treat type 2 diabetes when diet and exercise alone are insufficient. In other words, it’s the first mainstream, effective fat-loss pill. Just how popular is Ozempic? Novo Nordisk’s market cap has soared than $400 billion, which is greater than the annual GDP of its home country, Denmark! Meanwhile, EPS is set to grow from $4 to ~$8 by 2026 – massive for a company of this size. Eli Lilly, one of the world’s largest pharmaceutical companies, is launching two massive multi-billion-dollar drugs in 2023 – Donanemab (for Alzheimer’s disease) and Lebrikizumab (for eczema). Like NVO, Zacks Consensus Estimates suggest steady and consistent top and bottom-line growth in the coming quarters. AbbVie is launching Epcoritamab (for large B-cell lymphoma). ABBV has been a consistent winner since its inception. Bottom Line
Regarding biotech investing, seek quality companies with deep liquidity, strong profitability, and long “runways.” Stocks like NVO, LLY, and ABBV allow investors to do just that.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of
+46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance for information about the performance numbers displayed in this press release.